Summary
Thermo Fisher Scientific Inc. (TMO) reported strong performance for the second quarter and first six months of 2018, with total revenues increasing significantly year-over-year, driven by both organic growth and strategic acquisitions. The company demonstrated robust revenue growth across all its key business segments, particularly in Life Sciences Solutions and Laboratory Products and Services. Profitability also improved, with operating income and margin expanding, reflecting strong sales execution and operational efficiencies. The company's balance sheet shows a solid financial position, though cash and cash equivalents decreased compared to the prior year, likely due to investments and debt repayments. Significant investments were made in property, plant, and equipment, and the company announced plans for further acquisitions, signaling continued growth initiatives. Despite increased interest expenses due to higher debt levels, the company's liquidity remains strong, with ample capacity under its revolving credit facility to meet its financial obligations and fund ongoing operations and strategic growth plans.
Financial Highlights
55 data points| Revenue | $6.08B |
| Gross Profit | $2.74B |
| R&D Expenses | $242.00M |
| SG&A Expenses | $1.54B |
| Operating Expenses | $5.14B |
| Operating Income | $937.00M |
| Interest Expense | $170.00M |
| Net Income | $752.00M |
| EPS (Basic) | $1.87 |
| EPS (Diluted) | $1.85 |
| Shares Outstanding (Basic) | 403.00M |
| Shares Outstanding (Diluted) | 406.00M |
Key Highlights
- 1Total revenues for the six months ended June 30, 2018, increased by 22% to $11.93 billion, compared to $9.75 billion in the prior year period, driven by a substantial contribution from acquisitions and favorable currency translation.
- 2Operating income for the six months ended June 30, 2018, rose by 26% to $1.72 billion, with a corresponding increase in operating income margin to 14.4% from 14.0% in the prior year period.
- 3The Life Sciences Solutions segment showed a 11% revenue increase year-over-year for the six months ended June 30, 2018, and an improvement in operating income margin to 33.9%.
- 4The Laboratory Products and Services segment experienced significant revenue growth of 42% for the six months ended June 30, 2018, largely due to a major acquisition (Patheon), though its operating income margin slightly decreased.
- 5Despite an increase in long-term obligations to $17.71 billion from $18.87 billion, the company maintained a strong liquidity position, with $937 million in cash and cash equivalents and $2.50 billion available under its revolving credit facility.
- 6The company's effective tax rate for the second quarter of 2018 was 6.5%, with an expectation for the full year to be between 6% and 9%, benefiting from international operations and tax planning.
- 7Thermo Fisher Scientific announced plans to acquire Gatan, Inc. for approximately $925 million, indicating ongoing strategic inorganic growth initiatives.